Enhanced Liver Cancer Staging Systems Comparison
Explore the real-world performance of Barcelona Clinic Liver Cancer (BCLC) versus Hong Kong Liver Cancer (HKLC) staging systems in multiethnic Asian patients with Hepatocellular Carcinoma. Discover survival outcomes, treatment patterns, and patient characteristics based on the staging systems.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians Real-World Perspective ESPS Manuscript NO: 32584
Figure 1a. Barcelona Clinic Liver Cancer (BCLC) staging system2
Figure 1b. Hong Kong Liver Cancer (HKLC) staging system5
Figure 2a. Kaplan-Meier survival curve according to BCLC staging system BCLC Cumulative Survival 0 5 10 15 20 25 Survival Time (Years)
Figure 2b. Kaplan-Meier survival curve according to HKLC staging system HKLC Cumulative Survival 0 10 Survival Time (Years) 15 20 25 30 5
Figure 3. Patients receiving curative treatment after assignment to curative treatment groups by BCLC and HKLC staging systems Percentage HKLC Stage Va HKLC Curative Stages I, II and Va HKLC Stage I HKLC Stage II BCLC Curative Stages 0 and A BCLC Stage 0 BCLC Stage A *Figures in percentage
Figure 4. Comparison of characteristics of patients assigned by HKLC staging system to curative treatment who did and did not receive recommended treatment Received Curative Treatment p < 0.001 Did not Received Curative Treatment p < 0.001 100 92% 87.5% 90 p < 0.001 80 73.2% 70 65.5 Age (in years) / Percentage 60 60 p < 0.001 47.8% 50 41.4% p < 0.001 40 p < 0.001 26.8% 30 20 10.7% 10.8% 8.0% 10 1.8% 0 Age ECOG 0/1 ECOG 2-4 Child A Child B Child C
Figure 5. Median survival of patients assigned to curative treatment by BCLC and HKLC staging systems Cumulative Survival 15 20 25 30 0 5 10 Survival Time (Years)
Figure 6. Median survival of patients who received the assigned curative treatment according to the BCLC and HKLC staging systems Cumulative Survival 15 20 25 30 0 5 10 Survival Time (Years)
Table 1. Baseline characteristics Variable All Patients (n = 1,270) Age in years, median (range) 63 (13 to 94) Male, n (%) 1046 (82.4) Ethnicity Chinese 1135 (89.4) Malay 90 (7.1) Indian 36 (2.8) Others 9 (0.7) Aetiology Hepatitis B 953 (75.0) Hepatitis C 91 (7.2) Hepatitis B and C co-infection 48 (3.8) Others 178 (14.0) Child-Pugh class A:B:C 641 (50.5): 452 (35.6): 177 (13.9)
